Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
A leading nanotechnology company has returned to carry out another research project with Inhalation Research Services (IRS), ISAB’s contract research organization. The previous project, worth 584,000 SEK, began in February 2022. The new project, worth 491,000 SEK, will test slightly different versions of the company’s porous inhalable nanoparticles. Further studies with the same client are planned for later in 2022. A leading company in the field of nanoparticle drug delivery has returned to IRS to initiate a new research project following a successful collaboration earlier in the year. The client company is exploring the development of inhalable porous nanoporous particles for drug delivery.
The client chose to use ISAB’s intratracheal in vivo exposure module in its original project, a unique method that uses individual test rodents, unlike the ‘towers’ of multiple test rodents used in much conventional testing. It bypasses the animal’s nose and gently delivers aerosol directly to the lungs whilst carefully monitoring aerosol concentration and breathing patterns. The data generated is exceptionally precise and voluminous, evaluating how test particles dissolve in the lung, and how quickly they move into the bloodstream. ISAB CEO Manoush Masarrat:
“This client clearly appreciates the accuracy of the results we deliver and the difference we can make for them and their clients. We’re pleased to become the preferred supplier to a company of this stature and look forward to continuing the collaboration.”
